Diabetes Metab J.  2024 Jul;48(4):730-739. 10.4093/dmj.2023.0077.

Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial

• Lee JE
• Yu SH
• Kim SR
• Ahn KJ
• Song KH
• Lee IK
• Shon HS
• Kim IJ
• Lim S
• Kim DM
• Chung CH
• Lee WY
• Lee SH
• Kim DJ
• Cho SR
• Jung CH
• Jeon HJ
• Lee SH
• Park KY
• Rhee SY
• Kim SG
• Park SO
• Kim DJ
• Kim BJ
• Lee SA
• Kim YH
• Kim KS
• Seo JA
• Nam-Goong IS
• Lee CW
• Kim DK
• Kim SW
• Cho CG
• Kim JH
• Kim YJ
• Yoo JM
• Min KW
• Lee MK

• KMID: 2558040
• DOI: http://doi.org/10.4093/dmj.2023.0077

Abstract

Background
It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.
Methods
This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and <10.0%, low-density lipoprotein cholesterol (LDL-C) >100 and <250 mg/dL. One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). The primary efficacy endpoints were the percent changes in HbA1c and LDL-C levels from baseline at the end of the treatment.
Results
After 16 weeks of treatment compared to baseline, HbA1c showed a significant difference of 0.94% compared to the atorvastatin group in the combination group (0.35% vs. −0.58%, respectively; P<0.0001), whereas the proportion of patients with increased HbA1c was also 62% and 15%, respectively, showing a significant difference (P<0.001). The combination group also showed a significant decrease in LDL-C levels compared to the metformin group (−55.20% vs. −7.69%, P<0.001) without previously unknown adverse drug events.
Conclusion
The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin’s preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose.

Keyword

Atorvastatin; Diabetes mellitus; Dyslipidemias; Metformin

Figure

• 

  Fig. 1. Flow diagram of the study participants.

• 

  Fig. 2. (A) Least square (LS) mean percent change in glycosylated hemoglobin (HbA1c) level from baseline to weeks 8 and 16 in groups treated with a combination of metformin and atorvastatin (combination group), and atorvastatin alone (atorvastatin group) (LS mean differences: −0.55% [95% confidence interval, CI, −0.76 to −0.34; P<0.001] at 8 weeks; −0.94% [95% CI, −1.25 to −0.63; P<0.001] at 16 weeks). (B) LS mean percent change in low-density lipoprotein cholesterol (LDL-C) levels from baseline to weeks 8 and 16 in groups treated with a combination of metformin and atorvastatin (combination group), and metformin alone (metformin group) (LS mean differences: −44.95% [95% CI, −50.68 to −39.21; P<0.001] at 8 weeks; −47.51% [95% CI, −53.66 to −41.36; P<0.001] at 16 weeks). aP<0.001.

• 

  Fig. 3. (A) Least square (LS) mean percent change in low-density lipoprotein cholesterol (LDL-C) level from baseline to weeks 8 and 16 in groups treated with a combination of metformin and atorvastatin (combination group), and atorvastatin alone (atorvastatin group) (LS mean differences: −4.73% [95% confidence interval, CI, −10.13 to 0.68; P=0.0859] at 8 weeks; −9.43% [95% CI, −15.02 to −3.84; P=0.0011] at 16 weeks). (B) Mean percent change in glycosylated hemoglobin (HbA1c) level from baseline to week 8 and 16 in the combination, metformin, and atorvastatin group (combination vs. metformin; differences: 0.27% [95% CI, 0.09 to 0.44; P=0.0035] at 8 weeks and 0.33% [95% CI, 0.11 to 0.55; P=0.0035] at 16 weeks) (combination vs. atorvastatin; difference: −0.55% [95% CI, −0.76 to −0.34; P<0.001] at 8 weeks and −0.94 [95% CI, −1.25 to −0.63; P<0.001] at 16 weeks). aP<0.05, bP<0.001.

• 

  Fig. 4. (A) Percentages of patients achieving the low-density lipoprotein cholesterol target of <100 mg/dL after 16 weeks of treatment. (B) Percentages of patients achieving the glycosylated hemoglobin (HbA1c) targets of <6.5% or ≤7.0% after 16 weeks of treatment. aP<0.01, bP<0.05, cP<0.001.

• 

  Fig. 5. (A) Percentage of patients with increased glycosylated hemoglobin (HbA1c) in the combination and atorvastatin groups (15.02% vs. 62.07%) (least square [LS] mean differences: −46.55% [95% confidence interval, CI, −62.13 to −30.97; P<0.001]). (B) Extent of increased HbA1c in the combination and atorvastatin groups (LS mean differences: −0.44% [95% CI, −0.96 to 0.07; P=0.0880]). aP<0.001.

• 

Reference

1. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020; 10:14790.

2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157:107843.

3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87:4–14.

4. Eliasson B, Cederholm J, Eeg-Olofsson K, Svensson AM, Zethelius B, Gudbjornsdottir S, et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care. 2011; 34:2095–100.

5. McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, et al. Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2012; 35:1301–9.

6. Lee JE, Min SH, Lee DH, Oh TJ, Kim KM, Moon JH, et al. Comprehensive assessment of lipoprotein subfraction profiles according to glucose metabolism status, and association with insulin resistance in subjects with early-stage impaired glucose metabolism. Int J Cardiol. 2016; 225:327–31.

7. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol. 2006; 5:20.

8. Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017; 24:19–25.

9. Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021; 45:1–10.

10. Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A, et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015; 38:1858–67.

11. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008; 51:1552–3.

12. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994; 17:1093–9.

13. Duca FA, Cote CD, Rasmussen BA, Zadeh-Tahmasebi M, Rutter GA, Filippi BM, et al. Metformin activates a duodenal AMPKdependent pathway to lower hepatic glucose production in rats. Nat Med. 2015; 21:506–11.

14. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57:2444–52.

15. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–81.

16. Bae JC, Min KW, Kim YH, Kim KA, Hong EG, Park CY, et al. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): a multicentre, randomized, double-blind, controlled, phase 3 trial. Diabetes Obes Metab. 2019; 21:103–11.

17. Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, Sugawara M, et al. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes: lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study. Circ J. 2014; 78:2512–5.

18. Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte F, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016; 3:e000075.

19. Sun J, Yuan Y, Cai R, Sun H, Zhou Y, Wang P, et al. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. BMJ Open. 2015; 5:e007280.

20. Chung YR, Park SW, Choi SY, Kim SW, Moon KY, Kim JH, et al. Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. Cardiovasc Diabetol. 2017; 16:4.